Fingolimod for the treatment of relapsing multiple sclerosis.

abstract：INTRODUCTION:Patients with multiple sclerosis (MS) may suffer from spasticity and pain during their disease course. Baclofen, dantrolene, diazepam and gabapentin have been used as first-line options to treat these conditions, with modest results. Medical use of marijuana smoking has bypassed traditional clinical trials...

journal_title：Expert review of neurotherapeutics

authors： Fragoso YD,Carra A,Macias MA

更新日期：2020-08-01 00:00:00

abstract：:Post-traumatic headache (PTH) is a very controversial disorder, particularly when it comes to chronic PTH following mild closed head injury and headache attributed to whiplash injury. Nevertheless, mild traumatic brain injury is very common in Western societies, affecting approximately 1.8 million individuals in the U...

journal_title：Expert review of neurotherapeutics

authors： Obermann M,Holle D,Katsarava Z

更新日期：2009-09-01 00:00:00

abstract：:Zonisamide (Zonegran, Eisai, Inc.) is a broad spectrum antiepileptic drug indicated for use as adjunctive therapy in the treatment of partial seizures. Zonisamide has multiple mechanisms of action, which may explain widespread reports of its utility in focal epilepsy and generalized epilepsy, and for nonseizure disord...

journal_title：Expert review of neurotherapeutics

authors： Biton V

更新日期：2004-11-01 00:00:00

abstract：:Cluster headache is one of the primary headache disorders. It is considered the most severe headache syndrome known to humans. In most instances, this disorder is readily treatable when the correct medications are utilized at the correct dosages. Cluster headache treatment involves abortive, transitional and preventiv...

journal_title：Expert review of neurotherapeutics

authors： Rozen TD

更新日期：2002-05-01 00:00:00

abstract：:Currently approved medications to treat cognitive deficits in Alzheimer's disease are targeting relatively late neurotransmission alterations and, thus, new approaches are needed to improve the observed modest efficacy. Employing various combinations of existing drugs is one way to achieve this aim. We can attempt to ...

journal_title：Expert review of neurotherapeutics

authors： Sobow T

更新日期：2010-05-01 00:00:00

abstract：:This review evaluates the most recent evidence available on the potential of cannabinoid drugs to relieve spasticity and pain in multiple sclerosis. Many different drugs are used to control the symptoms of multiple sclerosis, periods of relapse and the progression of the disease but it is in the potential management o...

journal_title：Expert review of neurotherapeutics

authors： Smith PF

更新日期：2003-05-01 00:00:00

abstract：INTRODUCTION:Pharmaceutical companies and the NIH have invested heavily in a variety of potential disease-modifying therapies for Alzheimer's disease (AD) but unfortunately all double-blind placebo-controlled Phase III studies of these drugs have failed to show statistically significant results supporting their clinica...

journal_title：Expert review of neurotherapeutics

authors： Amanatkar HR,Papagiannopoulos B,Grossberg GT

更新日期：2017-01-01 00:00:00

abstract：:There is great concern over cardiovascular disease in the schizophrenic population owing to the high incidence of cardiovascular mortality. Increased cardiovascular mortality is related to lifestyle choices (e.g., smoking and sedentary lifestyle) and a high prevalence of comorbid medical conditions, including dyslipid...

journal_title：Expert review of neurotherapeutics

authors： Michelsen JW,Meyer JM

更新日期：2007-07-01 00:00:00

abstract：:Schizophrenia is a devastating psychiatric disorder; the diagnosis probably encompasses a number of illnesses with similar clinical presentations, complicating both treatment and studies into the pathology of the disorder. The development of antipsychotic medications revolutionized treatment for the disorder. However,...

journal_title：Expert review of neurotherapeutics

authors： Scarr E,Dean B

更新日期：2009-01-01 00:00:00

abstract：:Parkinson's disease is a chronic neurodegenerative disorder leading to progressive motor impairment for which there is no cure. Currently, the diagnosis is made by the presence of cardinal motor features and several associated non-motor symptoms. However, at this point, the underlying neuropathological changes are alr...

journal_title：Expert review of neurotherapeutics

authors： Akhtar RS,Stern MB

更新日期：2012-12-01 00:00:00

abstract：:Introduction: Despite increased interest in the pharmacotherapy of bipolar disorder during pregnancy and the postpartum period, management of the disorder during these critical periods in a woman's life remains challenging.Areas covered: The authors review the effect of pregnancy and the postpartum period on the cours...

journal_title：Expert review of neurotherapeutics

authors： Sharma V,Sharma P,Sharma S

更新日期：2020-04-01 00:00:00

abstract：UNLABELLED:Pediatric bipolar disorder (PBD) presents with severe affect dysregulation characterized by elated mood, irritability and depressive symptoms, often in the form of a mixed episode. Early recognition of the external clinical features and the underlying emotional processing circuitry will help us understand th...

journal_title：Expert review of neurotherapeutics

authors： Pavuluri MN,Passarotti A

更新日期：2008-09-01 00:00:00

abstract：:The number of patients who will develop metastatic spinal tumors is estimated to be between 5 and 10% of all cancer patients. As the therapy for systemic cancer improves, the number of patients developing symptomatic spinal tumors that require local therapy will increase. Over the last 10 years there has been a dramat...

journal_title：Expert review of neurotherapeutics

authors： Bilsky MH

更新日期：2005-11-01 00:00:00

abstract：INTRODUCTION:Friedreich ataxia (FRDA) is a progressive, inherited, neurodegenerative disease for which there is currently no cure or approved treatment. FRDA is caused by deficits in the production and expression of frataxin, a protein found in the mitochondria that is most likely responsible for regulating iron-sulfur...

journal_title：Expert review of neurotherapeutics

authors： Strawser C,Schadt K,Hauser L,McCormick A,Wells M,Larkindale J,Lin H,Lynch DR

更新日期：2017-09-01 00:00:00

abstract：:Evaluation of: Segal BM, Constantinescu CS, Raychaudhuri A et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a Phase II, double-blind, placebo-controlled, randomized, dose-ranging study. Lancet Neurol. 7, 796-804 (2008). ...

journal_title：Expert review of neurotherapeutics

authors： Longbrake EE,Racke MK

更新日期：2009-03-01 00:00:00

abstract：:Introduction: Vitamin and mineral nutritional supplements are becoming increasingly popular as alternative treatments for anxiety and depression, as issues such as side effects from medication, failure to respond to psychotherapy and workforce limitations pose barriers for successful treatment.Areas covered: This revi...

journal_title：Expert review of neurotherapeutics

authors： Blampied M,Bell C,Gilbert C,Rucklidge JJ

更新日期：2020-04-01 00:00:00

abstract：:Introduction: Most preventive migraine treatments modify the brain's excitation/inhibition balance and/or serotonin metabolism, which likely accounts for their unfavorable adverse effect profile. Novel biological therapies blocking CGRP transmission are effective and better tolerated, but they are expensive and may no...

journal_title：Expert review of neurotherapeutics

authors： Lisicki M,Schoenen J

更新日期：2020-03-01 00:00:00

abstract：:Cognitive behavioral therapy has been found to be efficacious in the treatment of generalized anxiety disorder (GAD). However, reviews of the clinical significance has indicated that approximately 50% of patients with GAD return to a 'well' status following treatment. So how might the field advance? One way is to base...

journal_title：Expert review of neurotherapeutics

authors： Heiden Cv

更新日期：2013-02-01 00:00:00

abstract：:The demographics of aging identify an immediate need for the early diagnosis and development of dementia prevention strategies. Recent neuropathological studies have pointed to the early involvement of the hippocampus and entorhinal cortex in the progression of Alzheimer's disease in the brain. In particular, these st...

journal_title：Expert review of neurotherapeutics

authors： Mosconi L,De Santi S,Rusinek H,Convit A,de Leon MJ

更新日期：2004-09-01 00:00:00

abstract：:Persistent gait deficits after stroke can cause falls, elevated energy cost and poor endurance. Coordination impairment is an underlying cause of gait deficits. Few efficacious interventions have been described that have targeted and measured restoration of coordinated gait components. Neuromuscular electrical stimula...

journal_title：Expert review of neurotherapeutics

authors： Daly JJ

更新日期：2006-10-01 00:00:00

abstract：:Management issues for patients with brain tumors include peritumoral edema, symptomatic seizures, venous thromboembolism, headache, pain, fatigue and neuropsychological complaints. Vasogenic edema is typically ameliorated with the lowest dose possible of corticosteroid. Seizures are managed with attention to additiona...

journal_title：Expert review of neurotherapeutics

authors： Daly FN,Schiff D

更新日期：2007-10-01 00:00:00

abstract：:Recent morphometric MRI studies have investigated brain volume abnormalities associated with the diagnosis of Alzheimer's disease (AD) using voxel-based morphometry (VBM). This technique allows the assessment of gray matter volumes in subjects with AD or related conditions compared with healthy controls in an automate...

journal_title：Expert review of neurotherapeutics

authors： Busatto GF,Diniz BS,Zanetti MV

更新日期：2008-11-01 00:00:00

abstract：:Alterations have been demonstrated in membrane phospholipid metabolism in Alzheimer's disease. Alterations in membrane phospholipid metabolite levels have been observed by 31P magnetic resonance spectroscopy 4 years before onset of cognitive changes. Implications of phospholipid membrane changes in Alzheimer's disease...

journal_title：Expert review of neurotherapeutics

authors： Pettegrew JW,McClure RJ

更新日期：2002-09-01 00:00:00

abstract：:Anaplastic astrocytomas (AA), WHO grade III gliomas, comprise 10-15% of all glial neoplasms. Currently, the only factors that have been shown to influence prognosis in patients with AA are age and Karnofsky performance status. Attempts have been made to identify biological prognostic factors for response to therapy an...

journal_title：Expert review of neurotherapeutics

authors： Chamberlain MC,Chowdhary SA,Glantz MJ

更新日期：2008-04-01 00:00:00

abstract：INTRODUCTION:Multiple Sclerosis is a chronic inflammatory demyelinating disease that affects 2.5 million people in the world. NEDA (No evidence of disease Activity) -4 is a new concept related to absence of disease activity in the context of MS. It takes into account the following four parameters: relapses; disability ...

journal_title：Expert review of neurotherapeutics

authors： Matta AP,Nascimento OJ,Ferreira AC,Magalhães TN,Benevides TP,Kirmse A,Dib JG,Cal H,Orsini M,Araujo LM

更新日期：2016-11-01 00:00:00

abstract：:The purpose of this article is to systematically review the use of fentanyl as an analgesic for breakthrough pain. This article found that the oral transmucosal fentanyl (OTFC) had a quicker onset to analgesia than oral immediate-release opioids. Intranasal fentanyl (INFS) had a quicker onset to analgesia than buccal ...

journal_title：Expert review of neurotherapeutics

authors： Davis MP

更新日期：2011-08-01 00:00:00

abstract：:Generalized anxiety disorder is characterized by excessive chronic anxiety in association with many somatic symptoms. The disorder has pervasive effects on quality of life, including work, social and educational aspects and requires long-term therapy. Available studies in patients are the Diagnostic and Statistical Ma...

journal_title：Expert review of neurotherapeutics

authors： Struzik L,Vermani M,Coonerty-Femiano A,Katzman MA

更新日期：2004-03-01 00:00:00

abstract：:Introduction: Alzheimer's Disease (AD) is a progressive neurodegenerative pathology characterized by the presence of neuritic plaques and neurofibrillary tangles. The most important markers in AD pathology include excessive accumulation of amyloid beta (Aβ42) and phosphorylated tau (P-tau) proteins. One of the possibl...

journal_title：Expert review of neurotherapeutics

authors： Baranowska-Wójcik E,Szwajgier D

更新日期：2020-03-01 00:00:00

abstract：:This article reviews the potential uses of complementary and alternative medicine (CAM) techniques for individuals with mood disorders. Mood disorders are among the most prevalent mental health issues today and there are many approaches towards their management. While many different types of medication are available, ...

journal_title：Expert review of neurotherapeutics

authors： Moss AS,Monti DA,Amsterdam JD,Newberg AB

更新日期：2011-07-01 00:00:00

abstract：:Glatiramer acetate (GA; Copaxone(®), Teva Pharmaceuticals Inc.), approved in the USA in 1996 and EU in 2001 as first-line treatment for relapsing-remitting multiple sclerosis, is now available in 51 countries and recently gained approval for delaying conversion to clinically definite multiple sclerosis in patients wit...

journal_title：Expert review of neurotherapeutics

authors： Johnson KP

更新日期：2012-04-01 00:00:00